Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 6, Issue 3, Pages e404-e404
Publisher
Springer Nature
Online
2016-03-11
DOI
10.1038/bcj.2016.9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*
- (2016) Clemens M. Wendtner et al. LEUKEMIA & LYMPHOMA
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
- (2014) A. P. Kater et al. BLOOD
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
- (2014) J.-F. Fecteau et al. BLOOD
- Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice
- (2013) Francesco Zaja et al. AMERICAN JOURNAL OF HEMATOLOGY
- IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
- (2012) Pietro Bulian et al. Journal of Translational Medicine
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
- (2011) X. C. Badoux et al. BLOOD
- Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
- (2011) Clemens-Martin Wendtner et al. LEUKEMIA & LYMPHOMA
- Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
- (2010) D. Oscier et al. HAEMATOLOGICA
- Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
- (2010) Christine I. Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
- (2010) Taimur Sher et al. LEUKEMIA & LYMPHOMA
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started